• Ligand Pharmaceuticals recently updated its long-term outlook, projecting 40% royalty revenue growth for 2026 and a 23% compound annual growth rate through 2030, supported by products including Filspari, Ohtuvayre and Capvaxive.
• The company also highlighted more than US$1.00 billion in deployable capital for new royalty deals targeting unmet medical needs, underlining its capacity to expand the portfolio further.
• We’ll now examine how this upgraded royalty growth outlook, underpinned by products like Filspari and Ohtuvayre, reshapes Ligand’s investment narrative.

These 19 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Ligand Pharmaceuticals Investment Narrative Recap

To own Ligand, you need to believe in the durability and expansion of its royalty model as partners commercialize key drugs like Filspari and Ohtuvayre. The upgraded outlook for 40% royalty growth in 2026 and a 23% CAGR through 2030 reinforces royalty-driven growth as the main near term catalyst. The biggest risk remains concentration in a handful of royalty assets, and this update does not remove the vulnerability to setbacks in those underlying products.

Among recent announcements, the new 2026 revenue guidance of US$245 million to US$285 million, including US$200 million to US$225 million in royalty revenue, ties directly into the company’s revised long term royalty growth projections. Together, the guidance and long term outlook frame how quickly royalties from products such as Filspari, Ohtuvayre and Capvaxive might scale, while also highlighting the execution risk if partner commercialization or pricing trends fall short of expectations.

Yet even with stronger royalty forecasts, investors should be aware that concentrated exposure to a few partnered drugs leaves Ligand vulnerable if...

Ligand Pharmaceuticals' narrative projects $315.6 million revenue and $121.1 million earnings by 2028. This requires 18.9% yearly revenue growth and a $197 million earnings increase from $-75.9 million today.

Uncover how Ligand Pharmaceuticals' forecasts yield a $243.44 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span a wide range, from US$38.77 up to about US$301.09, showing how far apart individual views can be. As you weigh those opinions, consider how much the business still depends on a concentrated set of royalty assets and what that could mean for future performance if any one of them stumbles.

Explore 3 other fair value estimates on Ligand Pharmaceuticals - why the stock might be worth as much as 46% more than the current price!

Build Your Own Ligand Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Ligand Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Ligand Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ligand Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.